Scottish National Investment Bank
31
24M
23
7.75
11
0.26
2
- Areas of investment
Investor highlights
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 31
- Lead investments
- 11
- Exits
- 2
- Rounds per year
- 7.75
- Follow on index
- 0.26
- Investments by industry
- Manufacturing (6)
- Electric Vehicle (5)
- Software (4)
- Automotive (3)
- Renewable Energy (3) Show 46 more
- Investments by region
- United Kingdom (26)
- United States (2)
- Peak activity year
- 2022
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 14
- Avg. valuation at time of investment
- 27M
- Group Appearance index
- 0.45
- Avg. company exit year
- 7
- Avg. multiplicator
- 33.87
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Orbex Space | 18 Apr 2024 | Aerospace, Autonomous Vehicles, Space Travel | Late Stage Venture | 22M | Scotland, United Kingdom, United Kingdom |
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Minghui Pharmaceutical | Nov 8, 2025 | Biopharmaceutical, Immunology, Oncology | Late stage | 131000000 USD |  Singapore |
| Sirius Therapeutics | Oct 5, 2025 | Cardiometabolic disorders, Chronic diseases, RNA delivery technologies, siRNA therapeutics | - | 50000000 USD |  San Diego, California |
| Rapafusyn | Aug 9, 2025 | Drug Development, Drug Discovery, Molecular Glue Therapeutics, Therapeutics | - | 44000000 USD | Baltimore, Maryland |
| PAQ Therapeutics | Jul 5, 2025 | Biotechnology, Cancer Treatment | - | 39000000 USD | Burlington, Massachusetts |
| Cargene Biopharma | Dec 15, 2021 | Biopharmaceutical, Cardiovascular Disease, Non-Alcoholic Steatohepatitis (NASH), Oligonucleotide Therapeutics | Early stage | 19200000 USD | Singapore |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.